Introduction
============

Diabetes is a major public health problem that is approaching epidemic proportions globally. According to the latest report from the IDF, the prevalence of diabetes will increase from 425 million persons in 2017 to 629 million by 2045 (IDF 2017^[1](#fn01){ref-type="fn"}^). Diabetic kidney disease (DKD, previously termed diabetic nephropathy, DN) is a microvascular complication and progresses gradually over many years in approximately 30--40% of individuals with T1D and T2D mellitus ([@B51]; [@B124]; [@B15]). DKD is now the main cause of chronic kidney disease (CKD) worldwide and the leading cause of end-stage-renal disease (ESRD) requiring renal replacement therapy (dialysis or transplantation). The presence of CKD is the single strongest predictor of mortality for persons with diabetes ([@B34]; [@B90]). Pathological findings in DKD include glomerular hypertrophy, mesangial matrix expansion, reduced podocyte number, glomerulosclerosis, tubular atrophy and tubulointerstitial fibrosis. Clinical criteria used to diagnose the subjects with DKD are urine ACR higher than 300 mg/g, while microalbuminuria is diagnosed when ACR is between 30--300 mg/g ([@B19]). Accumulating evidence has indicated that podocyte loss and epithelial dysfunction play important roles in DKD pathogenesis with further progression associated with inflammation but the exact molecular mechanisms responsible for DKD are not fully known ([@B13]; [@B100]; [@B43]).

Both clinical and epidemiological studies have demonstrated that there is familial aggregation of DKD in different ethnic groups, indicating that genetic factors contribute to development of the disease. Furthermore, genetic risk factors in DKD interact with the environmental factors (for example, lifestyle, diet and medication) ([@B38]; [@B82]; [@B125]; [@B62]). [Figure 1](#F1){ref-type="fig"} is a schematic diagram representing the relationship between genetic, epigenetic and environmental factors that are involved in the development and progression of DKD. Genetic studies of DKD are mainly focused on association analyses between genomic DNA variation (for example, single nucleotide polymorphisms, SNPs, copy number variants, CNVs, and microsatellites) and clinical phenotypes of the disease ([@B38]; [@B44]; [@B125]; [@B37]). Epigenetics studies of DKD examine potentially heritable changes in gene expression that occur without variation in the original DNA nucleotide sequence ([@B131]; [@B62]; [@B123]; [@B63]). Therefore, epigenetic studies of DKD may provide information to help understand how environmental factors modify the expression of genes that are involved in DKD progression. Combined genetic, epigenetic and phenotypic studies together may generate information to understand new pathogenic pathways and to search for new biomarkers for early diagnosis and prediction as part of prevention programs in DKD. The results may also be useful in finding novel targets for the treatment of DKD.

![This is a schematic diagram representing the relationship between genetic, epigenetic and phenotypic studies in diabetic kidney disease (DKD). Genetic association studies are fundamentally important for identification of susceptibility or resistance genes (G). Epigenetic studies analyzing genomic DNA methylation changes, chromosome histone modification and ncRNA regulation are useful for dissecting the interaction of the genes with environmental factors. The combined data from genetic, epigenetic and phenotypic (Phe) studies may provide the opportunity for us to understand new pathways underlying the pathogenesis of DKD and to discover new biomarkers for early diagnosis and to find targets for prevention and treatment programs of this disease. The different sizes of the 'G" and "Phe" represent the variation of genetic and phenotypic effects.](fgene-10-00507-g001){#F1}

SNPs are the most common form of genomic DNA variation. The updated dbSNP database of more than 500 million reference SNPs (rs) with allele frequency data^[2](#fn02){ref-type="fn"}^ has provided fundamental information for genetic studies of complex diseases including, DKD. The genetic studies in DKD have implicated previously unsuspected biological pathways and subsequently improved our knowledge for understanding of the genetic basis of the disease. For most common traits studied in DKD, however, the identified genes and their SNPs only explain a fraction of associated risk, suggesting that human genomic DNA variations are only a part of underlying susceptibility to DKD. This has led to evolving interest in epigenetics to help explain some of the missing heritability of DKD. Epigenetic mechanisms mainly consist of DNA methylation, chromosome histone modification and non-coding RNA (ncRNA) regulation ([@B62]; [@B10]). Epigenetic related ncRNAs include miRNA, siRNA, piRNA, and lncRNA ([@B56]). There are more than 30,000 identified CpG islands in the human genome. Detailed information for these CpG islands can be found in the public database^[3](#fn03){ref-type="fn"}^. The CpG islands are defined as stretches of DNA \> 200 bp long with a GC percentage greater than 50% and an observed-to-expected CpG ratio of more than 60%. The CpG islands are often found at promoters and contain the 5′ end of the transcript, while DNA methylation occurs at 5′-cytosines of "CpG" dinucleotides^[4](#fn04){ref-type="fn"}^ ([@B26]). In DKD, the effects of DNA methylation have been studied in terms of transgenerational inheritance of the disease to explore environmental and other non-genetic factors that may influence epigenetic modifications in the genes involved in DKD ([@B28]; [@B58]). Identification of differentially methylated CpG sites in promoters or other functional regions of genes and the analysis of the DNA methylation changes that are associated with DKD have become the most common approaches used in epigenetic studies of the disease ([@B131]; [@B62]; [@B123]). Furthermore, ncRNAs, particularly long ncRNAs are known to be involved in epigenetic processes. ncRNAs certainly play an important role in chromatin formation, histone modification, DNA methylation and consequently gene transcription silencing.

Genetic and epigenetic studies of DKD, initially using candidate gene approaches and more recently at genome-wide scale (known as GWAS and EWAS), have been undertaken to identify many genes conferring susceptibility or resistance to DKD. In this review, clinical phenotypes, research approaches and experimental designs that have been used for genetic and epigenetic studies of DKD are described. These research approaches and experimental designs can also be used for study of CKD. Current information from genetic and epigenetic studies of DKD is summarized. Further investigation of molecular defects in DKD with new generation sequencing analyses and phenome-wide association studies (PheWAS) are discussed.

Biological Material, Research Approaches and Study Designs Used in Genetic and Epigenetic Investigations of Diabetic Kidney Disease
===================================================================================================================================

Two major research approaches either at genome-wide scale or focused on candidate gene(s) have been widely used for comparative studies between cases (patients with DKD) and controls (diabetes patients without DKD). Case-control studies by recruiting large numbers of subjects can increase the statistical power of reported associations. The aim is to discover the genes presented differentially in genomic structure or genetic expression. Genome-wide or epigenome-wide association studies (GWAS or EWAS) are hypothesis-generating approaches ([@B98]; [@B32]; [@B66]). These study designs have benefited from rapid development of human genome research, including the creation of publicly available databases of SNPs, haplotypes and CpG islands and the rapid technical improvements in analyzing genomic variation using high-throughput techniques and high-density SNP or CpG arrays. Another approach is to focus on candidate genes and study a more limited number of genes potentially involved in the pathogenesis of DKD based upon our known knowledge or hypothesis. In genetic and epigenetic studies of DKD, DNA samples used are commonly extracted from peripheral blood samples because they are clinically accessible. [@B31] have comparatively analyzed DNA methylation changes related to BMI by using both approaches of whole-blood DNA methylation profiling and adipose tissue specific methylation measurement. Data suggests that analysis of blood DNA methylation is worthwhile because the results can reflect the DNA methylation changes in relevant tissues for a particular phenotype. Nevertheless, there is still limited information concerning the correlation between whole blood DNA methylation profiles and kidney tissue specific DNA methylation changes in part due to the heterogeneity of cell types within the kidney. To improve the tissue specific DNA methylation analysis of kidney diseases, including DKD, it is necessary to construct biobanks of renal biopsies. Karolinska Institutet has established a biobank in KaroKidney with more than 750 renal biopsies^[5](#fn05){ref-type="fn"}^. The advantages and limitations of these two approaches, as well as the clinical materials and experimental design used in genetic and epigenetic studies of DKD are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Clinical material, research approaches and experimental designs used in genetic and epigenetic studies of diabetic kidney disease.

                        Study                                                  Advantage                                                                       Disadvantage
  --------------------- ------------------------------------------------------ ------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  Clinical material     Blood or saliva                                        Clinical accessible                                                             Possible bias from mixed cell types
                        Kidney tissues                                         Gene specific methylation and expression can be analyzed                        Difficult to access
                        Renal cell lines                                       Intervention and mechanism study                                                *In vitro* experiment
  Research approach     Candidate gene DNA variation or methylation analysis   Study of candidate genes with potential biological functions                    Less information on the studied genes
                        Global genomic DNA variation or methylation analyses   General information of DNA polymorphisms and methylation in genome wide scale   Analysis of repeated sequence alteration and methylation changes Lack of gene specific information
                        Genome or epigenome-wide association studies           Numerous SNP, CNV or CpG sites methylation information in genome wide scale     Higher cost Strict validation is needed
  Experimental design   Case-control study                                     Many cohorts exist                                                              Difficult to control genetic and environmental confounders
                        Twin study                                             Control for genetics                                                            Few large cohorts
                        Family study                                           Study of potential inheritance                                                  Few large cohorts
                        Longitudinal study                                     Determine causality                                                             Time consuming

CNV, copy-number variation; CpG sites, the regions of DNA where a cytosine nucleotide is followed by a guanine nucleotide in the linear sequence of bases along its 5′ → 3′ direction; SNP, single-nucleotide polymorphism.

Recent Data From Genetic Studies in Diabetic Kidney Disease
===========================================================

Considerable amounts of data from genetic studies in DKD have accumulated. A list of the genes that are reported to be associated with susceptibility or resistance to DKD are summarized in [Table 2](#T2){ref-type="table"}. The genes are listed in alphabetical order. Surprisingly, there are more than 150 genes. Most of them have been identified by genetic association studies employing candidate gene approaches over the past 20 years. Furthermore, a number of GWAS in DKD have been published in the last 10 years. By using GWAS approaches, approximately 33 genes have been found to be associated with the DKD, i.e., *ABCG2, AFF3, AGER, APOL1, AUH, CARS, CERS2, CDCA7/SP3, CHN2, CNDP1, ELMO1, ERBB4, FRMD3, GCKR, GLRA3, KNG1, LIMK2, MMP9, NMUR2, MSRB3/HMGA2, MYH9, PVT1, RAET1L, RGMA/MCTP2, RPS12, SASH1, SCAF8/CNKSR3, SHROOM3, SLC12A3, SORBS1, TMPO, UMOD*, and *ZMIZ1* ([@B49]; [@B105], [@B102]; [@B72]; [@B122]; [@B14]; [@B89]; [@B48]; [@B121]; [@B71]; [@B101]; [@B22]; [@B129]). However, most of these genes (∼80%) reportedly associated with DKD still need to be confirmed by further replication studies and detailed analysis of their functional role in DKD in experimental models. Polymorphisms in these candidate genes association with DKD studies are listed in [Table 2A](#T2){ref-type="table"}, while their potential biological relevance and genetic effects in DKD are briefly described. Of them, 34 genes are originally predicted by GWAS and the statistical association with DKD summarized in [Table 2B](#T2b){ref-type="table"}.

###### 

Current data from genetic association studies in diabetic kidney disease by using candidate gene approach.

  Gene symbol          Genomic DNA polymorphisms                                                               Disease
  -------------------- --------------------------------------------------------------------------------------- -------------------------------------------
  *ABCG2*              rs2231142                                                                               T2D-uric acid
  *ACACB*              rs2268388                                                                               T2D-DKD
  *ACE*                rs4646994 (289bp Alu I/D), rs4343, rs1799752, rs1800764, rs12449782                     T1D-DKD, T2D-DKD, T2D-ESRD
  *ADPOQ*              rs266729, rs17300539, rs2241766, rs1063537, rs2241767, rs2082940                        T1D-DKD, T2D-DKD
  *ADRB2*              Arg16Gly, Gln27Glu                                                                      T2D-eGFR
  *AFF3*               rs7583877                                                                               T1D-ESRD
  *AGER*               rs2070600, rs2071288                                                                    T2D-DKD
  *AGT*                rs5050, rs4762, Met235Thr                                                               T2D-DKD
  *AGTR1*              rs5186, +1166A/C, -106C/T, rs12695897                                                   T1D-DKD, T2D-ESRD
  *AGTR2*              +1675G/A, +1818A/T                                                                      T1D-DKD
  *AKR1B1*             rs759853                                                                                T2D-DKD, T2D-ESRD
  *ALOX12*             rs14309                                                                                 T2D-DKD+CVD
  *APOE*               e4 allele, e2/e3 alleles                                                                T2D-DKD
  *APOL1*              rs136161, rs713753, rs767855, Ser342Gly, Ile384Met                                      T2D-ESRD
  *AUH*                rs773506                                                                                T2D-ESRD
  *BID*                rs181390                                                                                T1D-ESRD
  *CALD1*              rs3807337                                                                               T1D-DKD
  *CARS*               rs452041, rs739401                                                                      T1D-DKD, T2D-DKD
  *CASR*               rs3804594                                                                               T2D-DKD
  *CAT*                rs1001179                                                                               T2D-ESRD
  *CERS2*              rs267734, rs267738                                                                      T1D-DKD, T2D-DKD
  *CDH13*              rs11646213, rs3865188                                                                   T1D-ESRD
  *CFH*                rs379489                                                                                T2D-ESRD
  *CHN2*               rs39059                                                                                 T1D-DKD
  *CNDP1*              (CTG)5, rs4892249, rs6566815, rs2346061, rs1295330, rs6566810, rs11151964, rs17817077   T2D-dialysis, T2D-DKD, T1D-ESRD, T2D-ESRD
  *CNDP2*              rs7577, rs4892247                                                                       T2D-ESRD
  *CYP11B2*            -344T/C                                                                                 T2D-DKD
  *COQ5*               rs1167726, rs614226, rs1167725                                                          T1D-ESRD
  *COX6A1*             rs12310837                                                                              T1D-ESRD
  *COX10*              rs7213412                                                                               T1D-ESRD
  *CUBN*               rs1801239                                                                               T1D-albuminuria, T2D-ESRD
  *CYBA*               rs4673, rs9932581                                                                       T1D-ESRD, T2D-DKD
  *eNOS*               -786C/T, +786T/C, +894G/T, Glu298Asp                                                    T1D-DKD, T2D-DKD
  *ELMO1*              rs741301, rs1345365, rs11769038, rs10951509, rs1882080, rs6462776, rs6462777            T1D-DKD, T1D-ESRD, T2D-DKD
  *ENPP1*              rs1044498, rs7754586, rs1974201                                                         T1D-DKD, T2D-DKD, T2D-ESRD
  *EPHX2*              rs751141                                                                                T2D-DKD
  *EPO*                rs1617640                                                                               T1D-ESRD, T2D-DKD
  *ERBB4*              rs7588550                                                                               T1D-DKD
  *ESR1*               rs12197043, rs11964281, rs1569788, rs9340969                                            T2D-DKD
  *FNDC5*              rs16835198                                                                              T2D-DKD
  *FRMD3*              rs1888747, rs10868025, rs942280, rs942278, rs942263, rs1535753, rs2378658, rs13288659   T1D-ESRD, T2D-DKD
  *GAS6*               Intron 8, c.834+7G/A                                                                    T2D-DKD
  *GATC*               rs2235222, rs7137953                                                                    T1D-ESRD
  *GCK*                rs730947                                                                                T2D-ESRD
  *GCKR*               rs1260326                                                                               T2D-eGFR
  *GFPT2*              Ile147Val                                                                               T2D-DKD
  *GLRA3*              rs1564939                                                                               T1D-AER
  *GPX1*               rs3448                                                                                  T1D-DKD
  *GREM1*              rs1129456                                                                               T1D-DKD
  *GSTP1*              rs1695 (Ile105Val)                                                                      T2D-DKD, T2D-ESRD
  *H19-IGF2 cluster*   rs2839698, rs10732516, rs201858505                                                      T2D-DKD
  *HIF1α*              rs11549465 (Pro582Ser)                                                                  T1D-DKD, T2D-DKD
  *HO1*                -413T/A                                                                                 T2D-DKD
  *HSP70*              rs2763979, rs2227956                                                                    T2D-DKD
  *ICAM1*              rs5498                                                                                  T1D-DKD, T2D-DKD
  *IGFBP1*             rs1065780, rs3828998, rs3793344, rs4619                                                 T2D-DKD
  *IGF2BP2*            rs4402960                                                                               T2D-DKD
  *IL1α*               -889C/T                                                                                 T2D-DKD
  *IL1β*               rs16944, -511C/T                                                                        T2D-DKD
  *IL6*                -634G/C, -174G/C, rs1800796, rs1524107, rs1800795, rs1800796                            T2D-DKD
  *IL10*               -819T/C, -592A/C, -1082A/G                                                              T2D-DKD
  *IL18*               rs360719                                                                                T2D-DKD
  *INSR*               rs2059806                                                                               T2D-DKD
  *IRAK4*              rs4251532                                                                               T2D-DKD
  *KCNQ1*              I/D in intron 12, rs2237897                                                             T2D-eGFR, T2D-DKD
  *KLRA1*              rs2168749                                                                               T1D-ESRD
  *KNG1*               +7965C/T                                                                                T1D-DKD
  *LIMK2*              rs2106294                                                                               T2D-ESRD
  *LTA*                Thr60Asn                                                                                T1D-DKD
  *LRP2*               rs17848169                                                                              T2D-ESRD
  *MAPRE1P2*           rs1670754                                                                               T1D-ESRD
  *MCF2L2*             Leu359Ile                                                                               T1D-DKD
  *MGP*                -138T/C                                                                                 T2D-DKD
  *MME*                rs3796268, rs3773885                                                                    T1D-DKD
  *MMP12*              rs1277718, rs652438, Asn357Ser                                                          T1D-DKD
  *MMP9*               (CA)n in promoter, rs481480, rs2032487, rs4281481, rs3752462, rs3918242                 T2D-ESRD, T2D-DKD
  *NMUR2*              rs982715, rs4958531, rs4958532, rs4958535                                               T1D-DKD
  *MSC*                rs9298190                                                                               T1D-ESRD
  *MT2A*               rs28366003                                                                              T2D-DKD
  *MTHFR*              rs1801133                                                                               T1D-DKD, T2D-DKD
  *MTOR*               rs7212142                                                                               T2D-DKD
  *MyD88*              rs6853                                                                                  T2D-DKD
  *MYH9*               rs5750250                                                                               T2D-ESRD
  *NCALD*              rs1131863, +999T/A, +1298A/C, +1307A/G                                                  T2D-DKD
  *near IRS2*          rs1411766                                                                               T1D-DKD, T1D-ESRD, T2D-DKD
  *NOS2*               rs1137933                                                                               T2D-DKD
  *NOS3*               rs3918188, Glu298Asp, Gly894Thr                                                         T1D-DKD, T2D-DKD
  *NQO1*               rs1800566                                                                               T2D-DKD
  *NPHS1*              rs35238405                                                                              T2D-ESRD
  *NPY*                Leu7Pro                                                                                 T1D-DKD
  *PACRG*              rs2147653, rs1408705                                                                    T1D-ESRD
  *PAI1*               4G/5G                                                                                   T2D-DKD
  *PARK2*              rs4897081                                                                               T2D-DKD
  *PARP1*              C410T, G1672A, Val762Ala                                                                T2D-DKD
  *PFKFB2*             rs17258746, rs11120137                                                                  T2D-DKD
  *PLEKHH2*            rs1368086, rs725238, rs11886047                                                         T1D-DKD
  *PLXDC2*             rs1571942, rs12219125                                                                   T1D-DKD
  *PON1*               Leu55Met, Gln192Arg                                                                     T1D-DKD, T2D-ACR
  *PON2*               rs12704795                                                                              T2D-DKD
  *PPARG*              rs1805192, rs1801282                                                                    T1D-DKD, T2D-DKD
  *PPARG2*             Pro12Ala                                                                                T2D-eGFR, T2D-DKD
  *PPARGC1A*           Gly482Ser                                                                               T2D-DKD
  *PRKAA2*             rs2746342, rs10789038                                                                   T2D-DKD
  *PROX1*              rs340841                                                                                T2D-DKD
  *PSMD9*              rs1043307, rs14259, +460A/G, +437T/C, Glu197Gly                                         T2D-DKD
  *PRKCB1*             -1504C/T, -546C/T, -348A/G, -278C/T, -238C/G                                            T1D-DKD, T2D-eGFR
  *PTX3*               rs2305619, rs2120243                                                                    T2D-DKD
  *PVT1*               rs2648875, rs2720709                                                                    T2D-ESRD
  *RAGE*               -429T/C, -374T/A, +2184A/G                                                              T1D-ESRD, T2D-DKD
  *RAET1L*             rs1543547                                                                               T1D-DKD
  *RBP4*               rs3758538, rs10882278, rs7094671, rs12766992                                            T2D-eGFR
  *REN*                rs41317140                                                                              T2D-DKD
  *RREB1*              rs9379084, rs41302867                                                                   T2D-ESRD
  *TOP1MT*             rs7387720, 724037                                                                       T1D-ESRD
  *TXNRD2*             rs17745445, rs17745433, rs5992495, rs5992493                                            T1D-ESRD
  *RPS12*              rs7769051                                                                               T2D-ESRD
  *RTN1*               rs1952034, rs12431381, rs12434215                                                       T2D-ESRD
  *SASH1*              rs6930576                                                                               T2D-ESRD
  *SCAF8/CNKSR3*       rs12523833                                                                              T2D-DKD
  *SEMA6D/SLC24A5*     rs12917114                                                                              T1D-ESRD
  *SERPINB7*           rs1720843                                                                               T2D-DKD
  *SERPINE1*           4G/5G polymorphism                                                                      T2D-DKD
  *SHROOM3*            rs1739721                                                                               T2D-eGFR
  *SIK1*               rs2838302                                                                               T1D-ESRD
  *SIRT1*              rs4746720                                                                               T2D-DKD
  *SLC2A1*             rs3820589, HaeIII polymorphism                                                          T1D-DKD, T2D-DKD
  *SLC2A2*             +16459C/T                                                                               T1D-DKD
  *SLC2A9*             rs11722228, rs3775948                                                                   T2D-uric acid
  *SLC12A3*            rs11643718                                                                              T2D-DKD, T2D-ESRD
  *SOD1*               rs2234694                                                                               T1D-DKD
  *SOD2*               Ala9Val, Val16Ala                                                                       T1D-DKD
  *SORBS1*             rs1326934                                                                               T1D-DKD
  *SOX2*               rs11915160                                                                              T1D-DKD
  *SPTLC2*             rs176903                                                                                T1D-ESRD
  *SUMO4*              rs237025                                                                                T2D-DKD
  *SUV39H2*            rs17353856                                                                              T1D-DKD
  *TCF7L2*             rs7903146                                                                               T2D-DKD
  *TGFβ1*              rs1800470                                                                               T1D-DKD, T2D-DKD
  *THP*                rs12444268                                                                              T1D-DKD
  *TMPO*               rs4762495                                                                               T1D-ESRD
  *TNFα*               rs1800629, rs1800470, rs1800469, rs1800630, rs1799964                                   T2D-DKD, T2D-ESRD
  *TRAF6*              rs16928973                                                                              T2D-DKD
  *TRIB3*              rs2295490                                                                               T2D-DKD
  *UMOD*               rs12917707, rs13333226                                                                  T2D-DKD
  *VDR*                Raql variant                                                                            T2D-DKD
  *VEGF*               -1499C/T, rs2010963                                                                     T1D-DKD, T2D-DKD
  *VEGFA*              rs3025021                                                                               T1D-DKD
  *WNT4/ZBTB40*        rs12137135                                                                              T1D-ESRD
  *ZMIZ1*              rs1749824                                                                               T1D-ESRD
  *miRNA-146a*         rs2910164                                                                               T1D-DKD, T2D-DKD
  *miRNA-125*          rs12976445                                                                              T2D-DKD

###### 

Current data from genetic association studies in diabetic kidney disease by using genome wide association approach.

  Gene symbol    Genomic DNA polymorphisms                                                               *P*-value                                                   Disease                 References
  -------------- --------------------------------------------------------------------------------------- ----------------------------------------------------------- ----------------------- ------------------
  *ABCG8*        rs4148217                                                                               *P* = 0.003                                                 T2D-ESRD                [@B85]
  *AFF3*         rs7583877, rs7562121                                                                    *P* = 1.2 × 10(-8) and \<1 × 10(-6)                         T1D-ESRD                [@B105], [@B106]
  *AGER*         rs2070600, rs2071288                                                                    *P* \< 0.001                                                T2D-DKD                 [@B71]
  *AGTR1*        rs12695897                                                                              *P = 0.032*                                                 T2D-ESRD                [@B89]
  *APOL1*        rs136161, rs713753, rs767855                                                            *P* = 0.006--0.037                                          T2D-ESRD                [@B89]
  *AUH*          rs7735506                                                                               *P* = 2.57 × 10(-4)                                         T2D-ESRD                [@B76]
  *BID*          rs181390                                                                                *P* = 0.006                                                 T1D-ESRD                [@B25]
  *CARS*         rs452041, rs739401                                                                      *P* = 3.1 × 10(-6)                                          T1D-DKD, T2D-DKD        [@B96]
  *CERS2*        rs267734, rs267738                                                                      *P* = 0.0013 and 0.0015                                     T1D-DKD, T2D-DKD        [@B113]
  *CDCA7-SP3*    rs4972593                                                                               *P* = 5 × 10(-8)                                            T1D-ESRD in women       [@B104]
  *CHN2*         rs17157914                                                                              *P* = 0.029                                                 T2D-ESRD                [@B89]
  *CNDP1*        rs4892249, rs6566815                                                                    *P* = 0.0043 and 0.0076                                     T2D-ESRD                [@B89]
  *CNTNAP2*      rs1989248                                                                               *P \<* 1 × 10(-6)                                           T1D-ESRD                [@B106]
  *ELMO1*        rs741301 rs1345365, rs11769038, rs10951509, rs1882080, rs6462776, rs6462777             *P* = 0.004                                                 T2D-DKD                 [@B135]
  *ERBB4*        rs7588550                                                                               *P* = 2.1 × 10(-7)                                          T1D-DKD                 [@B105]
  *FRMD3*        rs942278, rs1888747, rs10868025, rs942280, rs942263, rs1535753, rs2378658, rs13288659   *P* = 5.0 × 10(-7)                                          T1D-ESRD, T2D-ESRD      [@B95]; [@B41]
  *GABRR1*       rs9942471                                                                               *P* = 4.5 × 10(-8)                                          T2D-DKD                 van Zuydam NR
  *GCKR*         rs1260326                                                                               *P* = 3.23 × 10(-3)                                         T2D-eGFR                [@B30]
  *GLRA3*        rs1564939                                                                               *P* = 0.0013                                                T1D-AER                 [@B103]
  KLKB           rs4253311                                                                               *P* = 5.5 × 10(-8)                                          Plasma renin activity   [@B70]
  *KNG1*         rs5030062                                                                               *P* = 0.001                                                 Plasma renin activity   [@B70]
  *LIMK2*        rs2106294, rs4820043                                                                    *P* = 7.49E-04 and 0.001                                    T2D-ESRD                [@B76]
  *MMP9*         rs481480, rs2032487, rs4281481                                                          *P* = 0.038, 0.045 and 0.048 *P* = 0.053, 0.054 and 0.055   T2D-ESRD T2D-DKD        [@B39]; [@B24]
  *MYH9*         rs5750250, rs92280                                                                      *P* = 4.3 × E(-4) *P* = 3 × 10(-7)                          T2D-ESRD                [@B41]; [@B76]
  *PTPN13*       rs61277444                                                                              *P* \< 1 × 10(-6)                                           T1D-DKD                 [@B106]
  *PVT1*         rs2648875, rs2720709                                                                    *P* = 1.8--2.1 × (-7)                                       T2D-ESRD                [@B49]
  *RAET1L*       rs1543547                                                                               *P* = 1 × 10(-5)                                            T1D-DKD                 [@B77]
  *RGMA-MCTP2*   rs12437854                                                                              *P* = 2 × 10(-9)                                            T1D-ESRD                [@B105]
  *RPS12*        rs9493454                                                                               *P* = 8.79 × 10(-4)                                         T2D-ESRD                [@B76]
  *SHROOM3*      rs1739721                                                                               *P* = 3.18 × 10(-3)                                         T2D-eGFR                [@B30]
  *SLC12A3*      rs11643718                                                                              *P* = 0.021                                                 T2D-DKD, T2D-ESRD       [@B120]
  *TMPO*         rs4762495                                                                               *P* = 0.0006                                                T1D-ESRD                [@B25]
  *UMOD*         rs12917707                                                                              *P* = 8.84 × 10(-4)                                         T2D-eGFR                [@B30]
  *ZMIZ1*        rs1749824                                                                               *P* = 8.1 × 10(-5)                                          T1D-ESRD                [@B25]

Data were extracted from more than 300 references in PubMed and most studies were carryout with genetic association study of candidate gene(s). CNVs, Copy Number Variants; DKD, Diabetic Kidney Disease; eGFR,

estimated Glomerular Filtration Rate

; T1D, Type 1 Diabetes Mellitus; T2D, Type 2 Diabetes Mellitus;

ABCG

, ATP Binding Cassette Subfamily G;

ACACB

, Acetyl-CoA Carboxylase Beta;

ACE

, Angiotensin I Converting Enzyme;

ADPOQ

, Adiponectin;

ADRB2

, Adrenoceptor Beta 2;

AFF3

, AF4/FMR2 Family Member 3;

AGER

, Advanced Glycosylation End-Product Specific Receptor;

AGT

, Angiotensinogen;

AGTR

, Angiotensin II Receptor;

AKR1B1

, Aldo-Keto Reductase Family 1 Member B;

ALOX12

, Arachidonate 12-Lipoxygenase, 12S Type;

ApoE

, Apolipoprotein E;

APOL1

, Apolipoprotein L1;

AUH

, AU RNA Binding Methylglutaconyl-CoA Hydratase;

BID

, BH3 Interacting Domain Death Agonist;

CALD1

, Caldesmon 1;

CaSR

, Calcium-Sensing Receptor;

CARS

, Cysteinyl-TRNA Synthetase;

CAT

, Catalase;

CERS2

, Ceramide Synthase 2;

CDCA7

, Cell Division Cycle Associated 7;

CDH13

, Cadherin 13;

CHN2

, Chimerin 2;

CNDP

, Carnosine Dipeptidase;

COQ5

, Coenzyme Q5, Methyltransferase;

COX6A1

, Cytochrome C Oxidase Subunit 6A1;

COX10

, COX10, Heme A:Farnesyltransferase Cytochrome C Oxidase Assembly Factor;

CUBN

, Cubilin; CYBA, Cytochrome B-245 Alpha Chain;

CYP11B2

, Cytochrome P450 Family 11 Subfamily B Member 2;

ELMO1

, Engulfment And Cell Motility 1;

eNOS

, Nitric Oxide Synthase;

ENPP1

, Ectonucleotide Pyrophosphatase/Phosphodiesterase 1;

EPO

, Erythropoietin;

EPHX2

, Epoxide Hydrolase 2;

ERBB4

, Erb-B2 Receptor Tyrosine Kinase 4;

ESR1

, Estrogen Receptor 1;

FRMD3

, FERM Domain Containing 3;

FNDC5

, Fibronectin Type III Domain Containing 5;

GAS6

, Growth Arrest Specific 6;

GATC

, Glutamyl-TRNA Amidotransferase Subunit C;

GCK

, Glucokinase;

GCKR

, Glucokinase Regulator;

GFPT2

, Glutamine-Fructose-6-Phosphate Transaminase 2;

GLRA3

, Glycine Receptor Alpha 3;

GPX1

, Glutathione Peroxidase 1;

GREM1

, Gremlin 1, DAN Family BMP Antagonist;

GSTP1

, Glutathione

S

-Transferase Pi 1;

HIF1α

, Hypoxia Inducible Factor 1 Subunit Alpha;

H19

, H19, Imprinted Maternally Expressed Transcript;

HMGA2

, High Mobility Group AT-Hook 2;

HO1

, Heme Oxygenase 1;

HSP70

, Heat Shock Protein 70;

ICAM1

, Intercellular Adhesion Molecule 1;

IGF2

, Insulin Like Growth Factor 2;

IGFBP1

, Insulin Like Growth Factor Binding Protein 1;

IL

, Interleukin;

IRAK4

, Interleukin 1 Receptor Associated Kinase 4;

INSR

, Insulin Receptor; IRS2, Insulin Receptor Substrate 2;

KCNQ1

, Potassium Voltage-Gated Channel Subfamily Q Member 1;

KLRA1

, Killer Cell Lectin Like Receptor A1;

KNG1

, Kininogen 1;

LTA

, Lymphotoxin Alpha;

LIMK2

, LIM Domain Kinase 2;

MAPRE1P2

, MAPRE1 Pseudogene 2;

MCF2L2

, MCF.2 Cell Line Derived Transforming Sequence-Like 2;

MGP

, Matrix Gla Protein;

MME

, Membrane Metalloendopeptidase;

MMP

, Matrix Metallopeptidase;

MSC

, Musculin;

MTHFR

, Methylenetetrahydrofolate Reductase;

MT2A

, Metallothionein 2A;

MSRB3

, Methionine Sulfoxide Reductase B3;

MTOR

, Mechanistic Target of Rapamycin Kinase;

MyD88

, Myeloid Differentiation Primary Response 88;

MYH9

, Myosin Heavy Chain 9;

NCALD

, Neurocalcin Delta;

NOS

, Nitric Oxide Synthase;

NQO1

, NAD(P)H Quinone Dehydrogenase 1;

NPHS1

, NPHS1, Nephrin;

NPY

, Neuropeptide Y;

PACRG

, Parkin Coregulated;

PAI1

, Plasminogen Activator Inhibitor 1;

PARK2

, Parkin RBR E3 Ubiquitin Protein Ligase;

PFKFB2

, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 2;

PLXDC2

, Plexin Domain Containing 2;

PLEKHH2

, Pleckstrin Homology, MyTH4 and FERM Domain Containing H2;

PON

, Paraoxonase;

PPARG

, Peroxisome Proliferators-Activated Receptor Gamma;

PPARGC1A

, Peroxisome Proliferators-Activated Receptor Gamma Co-activator 1 alpha;

PRKAA2

, Protein Kinase AMP-Activated Catalytic Subunit Alpha 2;

PROX1

, Prospero Homeobox 1;

PSMD9

, Proteasome 26S Subunit, Non-ATPase 9;

PRKCB1

, Protein Kinase C Beta;

PTX3

, Pentraxin 3;

PVT1

, Pvt1 Oncogene;

RAGE

, Advanced Glycosylation End-Product Specific Receptor;

RAET1L

, Retinoic Acid Early Transcript 1L;

RBP4

, Retinol Binding Protein 4; REN, Renin;

RGMA

, Repulsive Guidance Molecule BMP Co-Receptor A;

RREB1

, Ras Responsive Element Binding Protein 1;

TOP1MT

, DNA Topoisomerase I Mitochondrial;

RPS12

, Ribosomal Protein S12;

RTN1

, Reticulon 1; SASH1, SAM And SH3 Domain Containing 1;

SCAF8

, SR-Related CTD Associated Factor 8;

SEMA6D

, Semaphorin 6D;

SERPINB

, Serpin Family;

SHROOM3

, Shroom Family Member 3;

SIK1

, Salt Inducible Kinase 1;

SIRT1

, Sirtuin 1;

SLC2A

, Solute Carrier Family 2;

SLC12A3

, Solute Carrier Family 12 Member 3;

SOD

, Superoxide Dismutase;

SOX2

, SRY-Box 2;

SORBS1

, Sorbin and SH3 Domain Containing 1;

SP3

, Sp3 Transcription Factor;

SUMO4

, Small Ubiquitin-Like Modifier 4;

SUV39H2

, Suppressor Of Variegation 3-9 Homolog 2;

TCF7L2

, Transcription Factor 7 Like 2;

TGFβ1

, Transforming Growth Factor Beta 1;

TMPO

, Thymopoietin;

TNFα

, Tumor Necrosis Factor alpha;

THP

, Tamm-Horsfall protein;

TRAF6

, TNF Receptor Associated Factor 6;

TRIB3

, Tribbles Pseudokinase 3;

UMOD

, Uromodulin;

VEGF

, Vascular Endothelial Growth Factor;

VEGFA

, Vascular Endothelial Growth Factor A;

VDR

, Vitamin D Receptor;

WNT4

, Wnt Family Member 4;

ZBTB40

, Zinc Finger and BTB Domain Containing 40;

ZMIZ1

, Zinc Finger MIZ-Type Containing 1.

The *CNDP1* (carnosine dipeptidase 1) gene is located in chromosome 18q22.3 and contains 5-leucine (CTG) trinucleotide repeat length polymorphism (D18S880) in the coding region ([@B133]). This trinucleotide repeat polymorphism is found to have gender specificity and to confer the susceptibility for DKD and ESRD in T2D ([@B7]). Furthermore, serum carnosinase (CN-1) activity is negatively correlated with time on hemodialysis ([@B94]). In addition, several SNPs in this gene are also associated with DKD and ESRD ([@B57]; [@B40]; [@B75]; [@B9]; [@B81]; [@B4]; [@B21]; [@B65]). Interestingly, an experimental study in BTBR ob/ob mice has demonstrated that treatment with carnosine as the target of CNDP1 improves glucose metabolism and albuminuria, suggesting that carnosine may be a novel therapeutic strategy to treat patients with DKD ([@B6]).

The *ELMO1* (engulfment and cell motility 1) gene is located on chromosome p14.1 and encodes a member of the engulfment and cell motility protein family. The protein interacts with dedicator of cytokinesis proteins and subsequently promotes phagocytosis and cell migration. Increased expression of *ELMO1* and dedicator of cytokinesis 1 may promote glioma cell invasion ([@B91]). Furthermore, several SNPs in this gene are found to be associated with DKD in both T1D and T2D ([@B114], [@B115]; [@B25]; [@B67]; [@B95]; [@B50]; [@B135]; [@B5]; [@B18]; [@B52]; [@B78]; [@B112]). The variants associated with DKD, however, are different in the several populations studied, suggesting the presence of allelic heterogeneity probably resulting from the diverse ancestral genetic backgrounds of the different racial groups.

The *FRMD3* (FERM domain containing 3) gene is located in chromosome 9q21.32. The *FRMD3* gene is expressed in adult brain, fetal skeletal muscle, thymus, ovaries, and podocytes ([@B84]). [@B96] have demonstrated that *FRMD3* expression in kidneys of a DKD mouse model is decreased as compared with non-diabetic mice. Genetic polymorphisms in the *FRMD3* gene are associated with DKD and ESRD in T1D and T2D ([@B41]; [@B12]). Furthermore, the members of the bone morphogenetic protein (BMP) interact with *FRMD3*, which implies that *FRMD3* may influence the risk of DKD through regulation of the BMP pathway ([@B73]; [@B88]).

The *MMP9* (matrix metallopeptidase 9) gene is located in chromosome 20q13.12. The MMP family members are involved in the breakdown of extracellular matrix (ECM) in physiological processes, such as tissue remodeling, reproduction and embryonic development, while *MMP9* is the ninth member in the family. *MMP9* may play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Moreover, MMPs, including *MMP9*, are zinc-dependent endopeptidases and the major proteases in ECM degradation. There are common variants such as rs3918242 (-1562C/T) and microsatellites (CA)n in the promoter region and several SNPs rs481480, rs2032487, rs4281481, rs3752462 and rs3918242 are found to be associated with the susceptibility to DKD ([@B55]; [@B83]; [@B2]; [@B41]; [@B24]; [@B142]; [@B36]).

Both *UMOD* (uromodulin) and *SLC12A3* (solute carrier family 12 member 3) genes are located in the same chromosome but in short and long arms, respectively, i.e., 16p12.3 and 16q13. SLC12A3 is also known as thiazide-sensitive sodium-chloride cotransporter in kidney distal convoluted tubules, which is important for electrolyte homeostasis. Mutations in this gene are characterized by hypokalemic alkalosis combined with hypomagnesemia, low urinary calcium, but increased renin activity. [@B120] performed a GWAS in Japanese T2D subjects and reported that the *SLC12A3* Arg913Gln polymorphism was associated with reduced risk of DKD. [@B87] then conducted another 10-year longitudinal study in the same population. The results confirmed that the 913Gln allele of *SLC12A3* Arg913Gln polymorphism conferred a protective effect in DKD ([@B87]). More recently, [@B1] performed a further genetic study of *SLC12A3* polymorphisms in a Malaysian population, including the meta-analysis of the association between the *SLC12A3* Arg913Gln polymorphism and DKD from all the previous studies. *SLC12A3* Arg913Gln polymorphism was found to be associated with T2D (*P* = 0.028, OR = 0.772, 95% CI = 0.612--0.973) and DKD (*P* = 0.038, OR = 0.547, 95% CI = 0.308--0.973) in the Malaysian cohort. The meta-analysis confirmed the protective effects of the *SLC12A3* 913Gln allele in DKD (Z-value = -1.992, *P* = 0.046, OR = 0.792). In addition, the authors investigated the role of *slc12a3* expression in the progress of DKD with db/db mice and in kidney development with zebrafish embryos. With knockdown of zebrafish ortholog, slc12a3 led to structural abnormality of kidney pronephric distal duct at 1-cell stage. Slc12a3 mRNA and protein expression levels were upregulated in kidneys of db/db mice from 6, 12, and 26 weeks at the age. The authors thus concluded that *SLC12A3* is a susceptibility gene in DKD, while allele 913Gln but not allele Arg913 has a preventive effect in the disease ([@B1]). This association of the *SLC12A3* Arg913Gln polymorphism with DKD has been very recently replicated in a Chinese population ([@B141]). The *UMOD* gene encoded glycoprotein is synthesized exclusively in renal tubular cells and released into urine. Furthermore, UMOD may prevent urinary tract infection and inhibit formation of liquid containing supersaturated salts and subsequent formation of salt crystals. SNPs rs4293393 and rs1297707 in the *UMOD* gene are found to be associated with the susceptibility to DKD in T2D ([@B3]; [@B97]; [@B129]).

The Human Genome Project has revealed that there are more than twenty thousand protein coding genes, and probably more than one million of RNA genes^[6](#fn06){ref-type="fn"}^. Genetic association studies of RNA gene polymorphisms with DKD are very limited. Up to date, only two SNPs, i.e., rs2910164 and rs12976445 in the genes for miRNA-146a and miRNA-125 have been found to be associated with DKD in T1D and T2D ([@B69]; [@B59]). Further investigation of RNA genetic variation conferring susceptibility to DKD needs to be undertaken.

Current Information From Epigenetic Studies in Diabetic Kidney Disease
======================================================================

Similar to genetic association studies, epigenome-wide (EWAS) and candidate gene DNA methylation analyses have been used for epigenetic studies of DKD. Current information from epigenetic studies in DKD are represented in [Table 3](#T3){ref-type="table"}. An EWAS suggested that several genes, including *SLC22A12, TRPM6, AQP9, HP, AGTX*, and *HYAL2*, may have epigenetic effects in DKD ([@B130]). Interestingly, *SLC22A12* encodes for urate anion transporter 1 (URAT1), which is a kidney-specific urate transporter that transports urate across the apical membrane of the proximal tubule in kidneys. Loss-of-function *SLC22A12* mutations are associated with renal hypouricaemia and affected persons can develop exercise-induced acute kidney injury and are at increased risk of developing urate stones ([@B68]). TRPM6 is a member of transient receptor potential superfamily of cation channels. This gene is widely expressed in the body, including kidneys along the nephron. The TRPM6 channels are mainly located in the renal distal convoluted tubule, the site of active transcellular calcium and magnesium transport in the kidney ([@B35]). As described previously, several studies have implicated *UMOD* genetic polymorphisms in the susceptibility to DKD ([@B3]; [@B97]; [@B129]). A recent study has demonstrated that UMOD regulates renal magnesium homeostasis through TRPM6 ([@B86]). Furthermore, analyses of the candidate genes such as *IGFBP1* and *MTHFR* have also provided evidence that DNA methylation changes in these genes may be involved in the pathogenesis of DKD ([@B46], [@B45]; [@B137]). Combining and analyzing data from genetic and epigenetic studies together may help understand some of the pathophysiology in DKD.

###### 

Current information from epigenetic studies in diabetic kidney disease.

  Analysis                       Gene symbol/ Target                            Material and methods                                 Results                                                                                                                                             References
  ------------------------------ ---------------------------------------------- ---------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  DNA methylation                *AKR1B1, TIMP-2*                               T2DM-DKD                                             Hypomethylation of the genes are associated with albuminuria                                                                                        [@B8]
                                 ***AKR1B1, IGF1, SLC12A3***                    T2DM-DKD and ESRD                                    Those genes implicated in DKD based upon the inter-individual epigenetic differences                                                                [@B107]
                                 *CTGF*                                         T2DM-DKD Glomerular and mesangial cells              Hypomethylation through the decreased Dnmt3a binding in the gene promoter                                                                           [@B139]
                                 *IGFBP1*                                       T1DM-DKD                                             Hypermethylation                                                                                                                                    [@B45]
                                 *IL13RA1, IL15, EDG3, INHA*                    Hemodialyzed patients with DKD                       Hypermethylation                                                                                                                                    [@B64]
                                 *MTHFR*                                        Diabetic complications, including DKD                Hypermethylation                                                                                                                                    [@B33]
                                 *MTHFR*                                        T2DM-DKD                                             Demethylation                                                                                                                                       [@B137]
                                 *MIOX*                                         Human and mouse                                      Hypomethylation                                                                                                                                     [@B111]
                                 *PIK3C2B*                                      Glomeruli in DKD                                     Up-regulated with methylation in glomeruli                                                                                                          [@B132]
                                 *POLR2G, DDB1, ZNF230*                                                                              Down-regulated with methylation in glomeruli                                                                                                        
                                 *SLC30A8*                                      T2DM-DKD                                             Hypermethylation                                                                                                                                    [@B109]
                                 ***SLC22A12, TRPM6, AQP9, HP, AGXT, HYAL2***   Pre-diabetes and T2DM-DN                             Hypermethylation found in 174 of 694 CpG sites                                                                                                      [@B130]
                                 ***TAMM41, PMPCB, TSFM, AUH***                 T1DM-DKD                                             DNA methylation changes in these genes and influence with mitochondrial function                                                                    [@B119]
                                 ***UNC13B***                                   T1DM-DKD                                             An intronic polymorphism rs13293564 in the gene is associated with DKD DNA methylation levels in 19 CpG sites are changed                           [@B16]
                                 *KLF4*                                         Glomerular podocytes in human and mouse              DNA methylation levels in the promoters of genes encoding mesenchymal markers are increased                                                         [@B53]
                                 *aPC*                                          Podocytes                                            aPC epigenetically controls p66(Shc) expression                                                                                                     [@B17]
                                 *egfr*                                         Cultured proximal tubule (normal rat kidney) cells   Inhibition of histone deacetylase in eGFR                                                                                                           [@B42]
                                 *pxr*                                          db/db mice and proximal tubular cells                Demethylation of DNA                                                                                                                                [@B134]
                                 *dnmt1*                                        db/db mice                                           Hypomethylation                                                                                                                                     [@B140]
                                 *agt, abcc4, cyp4a10, glut5*                   db/m mouse                                           Hypomethylation                                                                                                                                     [@B74]
                                 *kif20b, cldn18, slco1a1*                                                                           Hypomethylation                                                                                                                                     
                                 *sglt2, pck1, g6pc, hnf4a*                     db/db mice                                           Demethylated in the proximal tubules                                                                                                                [@B74]
                                 *tgfb1, tet2*                                  db/db mice                                           Decreased DNA methylation                                                                                                                           [@B136]
  Histone modification           *MTHFR*                                        T2D with DN                                          MTHFR regulates histone modification rs1801133 C677T in the gene is associated with DN                                                              [@B143]
                                 *TGFB1*                                        Glomerular and mesangial cells                       TGF-β1 increases expression of the H3K4 methyltransferase SET7/9                                                                                    [@B117]
                                 *12/15-LO*                                     Glomerular and mesangial cells                       Up-regulation of histone lysine modifications                                                                                                       [@B138]
                                 *h3k9/14ac, at1r*                              Glomerular and mesangial cells db/db mice            Losartan attenuated increased H3K9/14Ac at RAGE, PAI-1 and MCP-1 promoters, while the chromatin state at these genes are mediated in part by AT1R   [@B99]
                                 *h3k9, h3k23*                                  db/db and C57BL/6 mice                               Acetylation                                                                                                                                         [@B108]
                                 *h3k4* in serine 10                                                                                 Demethylation and phosphorylation                                                                                                                   
                                 *h3k9/14ac*                                    db/+ mice                                            Losartan reversed permissive epigenetic changes in renal glomeruli                                                                                  [@B99]
                                 *set7/9*                                       db/db mice                                           Induced histone modification and mcp-1 expression                                                                                                   [@B23]
                                 *xbp1*                                         db/db mice                                           XBP1s-mediated of histone SET7/9 and consequently decreased MCP-1 expression                                                                        [@B23]
                                 *opn/h3k27me3*                                 Sur1-E1506K mice                                     Histone modification with *opn*                                                                                                                     [@B20]
                                 *txnip, h3k9ac, h3k4me3, h3k4me1, h3k27me3*    Sur1-E1506K mice                                     Histone acetylation changes                                                                                                                         [@B27]
                                 *egfr*                                         Cultured proximal tubule (normal rat kidney) cells   Inhibition of histone deacetylase in eGFR                                                                                                           [@B42]
                                 *grp78/histone h4*                             Diabetic rats                                        Acetylation changes                                                                                                                                 [@B118]
                                 *mfn2*                                         Diabetic rats                                        Histone acetylation at collagen IV promoter                                                                                                         [@B79]
                                 h3 and hsp-27, map kinase p28                  Sprague-Dawley rats                                  Dephosphorylation and acetylation of h3                                                                                                             [@B126]
  Non-coding RNA dysregulation   miR-9-3, miR34a, miR-137                       DKD and diabetic retinopathy                         DNA methylation changes                                                                                                                             [@B33]
                                 miR-199b-5p, klotho                            T2DM-DKD and STZ mice                                Increased serum klotho levels are mediated by miR-199b-5p                                                                                           [@B60]
                                 microRNA Let-7a-3                              T2DM with DKD                                        DNA methylation levels in the promoter are increased by targeting UHRF1                                                                             [@B93]
                                 microRNA 1207-5P                               Glomerular and mesangial cells                       This PVT1-derived microRNA is upregulated by glucose and TGF-β1                                                                                     [@B11]
                                 *creb1*, miR-10a                               HFD/STZ mice                                         This microRNA regulate epigenetic modification by targeting creb1                                                                                   [@B110]

DKD, Diabetic Kidney Disease; T1D, Type 1 Diabetes; T2DM, Type 2 Diabetes. The genes predicted by epigenome-wide association analysis are shown in bold, while genes from rodent studies are shown in lower case.

AKR1B1

, Aldo-Keto Reductase family 1, member B1;

aPC

, activated Protein C;

AQP9

, Aquaporin;

AT1R

, Angiotensin II Receptor type 1;

AUH

, AU RNA binding protein/enoyl-CoA hydratase;

EGFR

, epidermal growth factor receptor;

CTGF

, Connective Tissue Growth Factor;

DDB1

, Damage Specific DNA Binding Protein 1;

EDG3

, Endothelial Differentiation G-protein coupled receptor 3;

DNMT1

, DNA methyltransferase 1;

HFD

, High Fat Diet;

IGF1

, Insulin like Growth Factor 1;

IGFBP1

, Insulin-like Growth Factor Binding Protein 1;

IL13RA1

, interleukin 13 receptor subunit alpha 1;

IL15

, Interleukin 15;

INHA

, Inhibin alpha;

KLF4

, Kkruppel-like factor 4;

MTHFR

, Methylenetetrahydrofolate Reductase;

MIOX

, Myo-Inositol Oxygenase;

PIK3C2B

, Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Beta;

PMPCB

, Peptidase, Mitochondrial Processing beta subunit;

POLR2G

, RNA Polymerase II Subunit G;

SLC12A3

, Solute Carrier family 12 member 3;

SLC22A12

, Solute Carrier family 22 member 12;

SLC30A8

, Solute Carrier family 30 member 8;

TAMM41

, TAM41 Mitochondrial translocator assembly and maintenance homolog; tet2, tet methylcytosine dioxygenase 2;

TIMP2

, TIMP metallopeptidase inhibitor 2;

TRPM6

, Transient Receptor Potential cation channel subfamily M member 6;

TSFM

, Ts translation elongation Factor, Mitochondrial;

UHRF1

, Ubiquitin like with PHD and Ring Finger domains 1; UNC13B, Unc-13 homolog B member 3;

XBP1

, X-Box Binding Protein 1;

ZNF230

, Zinc Finger Protein 230;

12/15-LO

, 12/15-lipoxygenase;

TGFB1

, Transforming Growth Factor Beta 1.

ncRNAs regulate gene expression at the post-transcriptional level and are involved in chromatin histone modification. Most of studies concerning histone modification and ncRNA dysregulation have been performed in diabetic animal models, while a few studies have been undertaken in subjects with DKD ([Table 3](#T3){ref-type="table"}). [@B99] have analyzed histone modification profiles in genes associated with DKD pathology and the modified regulation of these genes following treatment with the angiotensin II type 1 receptor (AT1R) blocker losartan. The data indicate that losartan attenuates key parameters of DKD and modifies gene expression, and reverses some epigenetic changes in db/db mice. Losartan also attenuates increased H3K9/14Ac at RAGE, PAI-1, and MCP-1 promoters in mesangial cells cultured under diabetic conditions ([@B99]). In a recent study of subjects of T2D and diabetic complications (including DKD) ([@B33]) the methylation profiles of miR gene were compared and related to the presence of diabetic complications. Results indicated that miRs can modulate the expression of a variety of genes and methylation changes of *miR*-*9*-*3, miR*-*34a*, and *miR*-*137* were found to be associated with diabetic complications ([@B33]). These two studies provide evidence suggesting that therapies targeting epigenetic regulators might be beneficial in the treatment of DKD.

Summary and Perspectives
========================

Researchers have made major efforts to undertake well powered genetic and epigenetic studies in DKD to help understand its pathogenesis. The data, however, need to be confirmed by several strategies, for instance, replication studies could be performed with better selection of subjects with similar genetic background to limit influences from migration; intermarriage; cultural preferences; coupled with further investigation of DNA variation and methylation changes in RNA regulation genes and biological experiments to determine functional impact of these variants. Furthermore, new technologies for DNA and ncRNA sequencing analysis such as third generation sequencing and a PheWAS approach have recently been developed.

New Generation Sequencing
-------------------------

DNA sequencing analysis is used for determining the accurate order of nucleotides along chromosomes and genomes. Second-generation sequencing, commonly known as next-generation sequencing (NGS), has presently become popular in DNA sequencing analysis because NGS can enable a massively-paralleled approach capable of producing large numbers of reads at high coverages along the genome and therefore dramatically reduce the cost of DNA sequencing analysis ([@B127]; [@B47]; [@B80]). Today, third-generation sequencing (often called as long-read sequencing) is a new generation sequencing method, which works by reading the nucleotide sequences at single molecule level in contrast to the first and second generations of DNA sequencing ([@B128]). Moreover, it is necessary to develop the molecular instruments for whole genome sequencing to make this new generation sequencing commercially available. The advanced sequencing technologies will improve genetic and epigenetic studies in DKD in the near future.

ncRNA Genetic and Epigenetic Studies
------------------------------------

In the human genome, RNA genes are much more abundant than protein coding genes, while ncRNAs mainly include miRNAs and lncRNAs. Both forms of ncRNAs have been found to be involved in chromatin histone modifications, and subsequently can have epigenetic effects on the target genes. Therefore, identification of RNA genetic variation and investigation of biological alteration of these RNA genes should be included in research plans. Kato has very recently pointed out a hypothesis that transforming growth factor-β (TGF1β) may play an important role in early stage development of DKD, while some miRNAs and lncRNAs regulate the key molecules in the TGF1β pathway. These ncRNAs may be served as biomarkers for predicting the potential targets for prevention and treatment in DKD ([@B61]). Furthermore, [@B116] have compared Sanger sequencing and NGS to validate the five top ranked miRNAs that are predicted to be associated with DKD by EWAS. This study suggests that targeted NGS may offer a more cost-effective and sensitive approach and implied that the methylated miR-329-2, in which region SNP rs10132943 is located, and miR-429 where SNPs rs7521584 and rs112695918 exist, are associated with DKD ([@B116]). Although these two studies are preliminary, they may be good examples to help direct further DKD research.

Phenome-Wide Association Study (PheWAS)
---------------------------------------

PheWAS is a new approach to analyze many phenotypes in comparison with a single genetic variant. This approach was originally described using electronic medical record (EMR) data from EMR-linked with a DNA biobank and also can be combined with GWAS and EWAS. Therefore, PheWAS has become a powerful tool to investigate the impact of genetic variation on drug response among many individuals and may expand our knowledge of new drug targets and effects ([@B92]; [@B29]; [@B101]). Clearly, combined with GWAS and EWAS, PheWAS will provide us with the possibility to discover the associations with drug effects, including therapeutic response and side effect profiles in DKD ([@B54]).

Taken together, application of these advanced studies in DKD will be very useful not only for evaluating current data from genetic and epigenetic studies but also for generating new knowledge for dissecting the complexity of this disease.
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ACR

:   albumin-to-creatinine ratio
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